NYSE - Nasdaq Real Time Price USD
Qiagen N.V. (QGEN)
39.05 +1.84 (+4.96%)
As of 10:25:43 AM EDT. Market Open.
Trade QGEN on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for QGEN
- Previous Close
37.20 - Open
38.33 - Bid 38.80 x 10000
- Ask 38.86 x 100000
- Day's Range
38.27 - 39.20 - 52 Week Range
32.53 - 57.82 - Volume
657,151 - Avg. Volume
2,113,895 - Market Cap (intraday)
8.053B - Beta (5Y Monthly) 0.66
- PE Ratio (TTM)
19.92 - EPS (TTM)
1.96 - Earnings Date (est.) Aug 4, 2026
- Forward Dividend & Yield 0.35 (0.94%)
- Ex-Dividend Date Jul 7, 2026
- 1y Target Est
43.96
Recent News
View More
Performance Overview
Trailing total returns as of 6/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
QGEN
13.18%
S&P 500 (^GSPC)
7.98%
1-Year Return
QGEN
16.90%
S&P 500 (^GSPC)
21.33%
3-Year Return
QGEN
13.37%
S&P 500 (^GSPC)
69.98%
5-Year Return
QGEN
18.48%
S&P 500 (^GSPC)
73.24%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/23/2026
Market Cap
7.67B
Enterprise Value
8.67B
Trailing P/E
18.96
Forward P/E
11.70
PEG Ratio (5yr expected)
0.94
Price/Sales (ttm)
3.64
Price/Book (mrq)
2.30
Enterprise Value/Revenue
4.13
Enterprise Value/EBITDA
12.49
Financial Highlights
Profitability and Income Statement
Profit Margin
19.16%
Return on Assets (ttm)
6.01%
Return on Equity (ttm)
11.93%
Revenue (ttm)
2.1B
Net Income Avi to Common (ttm)
402.16M
Diluted EPS (ttm)
1.96
Balance Sheet and Cash Flow
Total Cash (mrq)
646.29M
Total Debt/Equity (mrq)
50.04%
Levered Free Cash Flow (ttm)
238.87M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
201.10
+7.77%
Mkt Cap 9.686B
Industry Diagnostics & Research
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreQiagen Earnings: Guidance Cut as Geopolitical Tensions Weaken Demand; Shares Undervalued
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
RatingPrice TargetQiagen Earnings: Guidance Cut as Geopolitical Tensions Weaken Demand; Shares Undervalued
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
RatingPrice TargetQiagen Earnings: Guidance Cut as Geopolitical Tensions Weaken Demand; Shares Undervalued
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
RatingPrice TargetAfter a Long Reset Period, Life Science Stocks Look Set to Rebound
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
RatingPrice Target